Hoth Therapeutics Inc. is a development stage biopharmaceutical company. It focused on therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. The company's BioLexa(TM) Platform is a proprietary, patented drug compound platform. Hoth Therapeutics Inc. is based in New York, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-8.19M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.75 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -114.32% |
| Return on Assets (Trailing 12 Months) | -105.92% |
| Current Ratio (Most Recent Fiscal Quarter) | 27.54 |
| Quick Ratio (Most Recent Fiscal Quarter) | 27.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.73 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.17 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.07 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 13.26M |
| Free Float | 12.34M |
| Market Capitalization | $17.10M |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | 0.66 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.92% |
| Percentage Held By Institutions (Latest 13F Reports) | 7.08% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |